Definitive Contract 75F40124C00134
Award Date
9/24/24
Potential Completion Date
2/2/26
Potential Value
$1.3M
Federal Agency
Food and Drug Administration
Awardee
PPD Development LP
Ultimate Awardee
Not listed
PSC Category
AJ11 - General Science And Technology R&D Services; General Science And Technology; Basic Research
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Time and Materials
Place of Performance
Cape Fear, NC 28401, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $724,461 firm-fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The contract is for the Cardiovascular-Kidney-Metabolic (CKM) Syndrome Patient-Reported Outcome (PRO) Burden Measure project, referenced as FDABAA-24-00123, with a performance period ending on November 15, 2026. PPD Development LP has significant experience supporting federal...
This is a $563,173 time and materials contract awarded to PPD Development LP by the Food and Drug Administration (FDA) to assess clinical site readiness and support enrollment of underrepresented minorities in medical device clinical trials. The contract has a performance period through December 2025 and is not set aside for any particular business type. PPD Development LP is a global contract research organization (CRO) that provides comprehensive clinical trial support services to federal...
This is a $324,420.00 firm fixed-price delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO). The contract is for research and development services related to clinical studies in the Blueprint MedTech program, including clinical study protocol development. The contract has a 5-year period of performance from June 17, 2024 to June 16, 2029, with a base period and two option units. PPD...
This is a Cost Plus Fixed Fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to PPD Development LP, a global contract research organization (CRO). The contract, valued at $66,339,562.95, is for the TAS::75 0885::TAS NIAID DAIT CLINICAL SITE MONITORING CENTER and has a performance period ending on February 23, 2023. PPD Development LP, a subsidiary of Thermo Fisher...
This is a $1,345,959.23 firm-fixed-price delivery order awarded by the U.S. Army Medical Command (MEDCOM) to PPD Development LP, a global contract research organization. The order is for FDA regulatory compliance training and is part of the parent Medical Product Research and Development indefinite delivery/indefinite quantity (IDIQ) contract. PPD Development LP is a subsidiary of Thermo Fisher Scientific and has been providing a wide range of services to federal agencies, including clinical...
This is a federal contract award to PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $139,861,060.22, is for NIAID Clinical Site Monitoring services. This is a definitive contract with a cost-plus-fixed-fee pricing type, with a period of performance through January 31, 2024. The...
This is a cost-plus-fixed-fee definitive contract awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to PPD Development LP, a global contract research organization (CRO), for R&D services related to biomedical basic research. The $27,437,431.92 contract has a performance period ending on October 31, 2021 and is not set aside for any specific business type. PPD Development LP has been awarded over $500 million in prime federal...
This federal contract award is for regulatory consulting assistance and research and development for clinical studies in the Blueprint MedTech program, which is managed by the National Institute on Drug Abuse (NIDA), a civilian agency. The award was made to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The contract has a period of performance from September 15, 2023 to September 14, 2024, with a ceiling value of $64,107.00. This...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services (HHS), to PPD Development LP, a global contract research organization (CRO). The contract, valued at $64,031,927.00, is for completing the ACTIV 2 study to support COVID-19 research. The contract is a cost-plus-fixed-fee type and does not have a set-aside designation. PPD Development LP is a subsidiary of Thermo Fisher...
This is a $5,758,524.34 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to PPD Development LP, a global contract research organization (CRO). The contract is to provide monitoring services for a Phase III clinical trial, specifically trial A5300B/PHOENIX. It is a cost-plus-fixed-fee contract with an ultimate completion date of December 14, 2025. The contract was awarded on April 15, 2019 and is not...